212 related articles for article (PubMed ID: 20818439)
1. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification.
Takenobu H; Shimozato O; Nakamura T; Ochiai H; Yamaguchi Y; Ohira M; Nakagawara A; Kamijo T
Oncogene; 2011 Jan; 30(1):97-105. PubMed ID: 20818439
[TBL] [Abstract][Full Text] [Related]
2. Role of stemness-related molecules in neuroblastoma.
Kamijo T
Pediatr Res; 2012 Apr; 71(4 Pt 2):511-5. PubMed ID: 22430387
[TBL] [Abstract][Full Text] [Related]
3. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases.
Boivin D; Labbé D; Fontaine N; Lamy S; Beaulieu E; Gingras D; Béliveau R
Biochemistry; 2009 May; 48(18):3998-4007. PubMed ID: 19296573
[TBL] [Abstract][Full Text] [Related]
4. The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation.
Peterson S; Bogenmann E
Oncogene; 2004 Jan; 23(1):213-25. PubMed ID: 14712226
[TBL] [Abstract][Full Text] [Related]
5. Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth.
Ruan H; Luo H; Wang J; Ji X; Zhang Z; Wu J; Zhang X; Wu X
Biochim Biophys Acta; 2016 Sep; 1860(9):1961-72. PubMed ID: 27316313
[TBL] [Abstract][Full Text] [Related]
6. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
Sartelet H; Imbriglio T; Nyalendo C; Haddad E; Annabi B; Duval M; Fetni R; Victor K; Alexendrov L; Sinnett D; Fabre M; Vassal G
Histopathology; 2012 Jun; 60(7):1144-55. PubMed ID: 22394107
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.
Zhu W; Hai T; Ye L; Cote GJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677
[TBL] [Abstract][Full Text] [Related]
8. RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line.
Futami H; Sakai R
Cancer Sci; 2009 Jun; 100(6):1034-9. PubMed ID: 19320641
[TBL] [Abstract][Full Text] [Related]
9. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma.
Cournoyer S; Nyalendo C; Addioui A; Belounis A; Beaunoyer M; Aumont A; Teira P; Duval M; Fernandes K; Fetni R; Haddad E; Sartelet H
Genes Chromosomes Cancer; 2012 Aug; 51(8):792-804. PubMed ID: 22514116
[TBL] [Abstract][Full Text] [Related]
10. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.
Tian X; Hou W; Bai S; Fan J; Tong H; Xu H
Int J Oncol; 2014 Jul; 45(1):121-8. PubMed ID: 24789807
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma.
Tong QS; Zheng LD; Tang ST; Ruan QL; Liu Y; Li SW; Jiang GS; Cai JB
World J Pediatr; 2008 Feb; 4(1):58-62. PubMed ID: 18402255
[TBL] [Abstract][Full Text] [Related]
12. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model.
Coulon A; Flahaut M; Mühlethaler-Mottet A; Meier R; Liberman J; Balmas-Bourloud K; Nardou K; Yan P; Tercier S; Joseph JM; Sommer L; Gross N
Neoplasia; 2011 Oct; 13(10):991-1004. PubMed ID: 22028624
[TBL] [Abstract][Full Text] [Related]
13. Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation.
Shimozato O; Waraya M; Nakashima K; Souda H; Takiguchi N; Yamamoto H; Takenobu H; Uehara H; Ikeda E; Matsushita S; Kubo N; Nakagawara A; Ozaki T; Kamijo T
Oncogene; 2015 Apr; 34(15):1949-60. PubMed ID: 24882578
[TBL] [Abstract][Full Text] [Related]
14. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray.
Mehrazma M; Madjd Z; Kalantari E; Panahi M; Hendi A; Shariftabrizi A
Fetal Pediatr Pathol; 2013 Jun; 32(3):192-204. PubMed ID: 22830353
[TBL] [Abstract][Full Text] [Related]
15. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
16. Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase.
Ishida M; Ichihara M; Mii S; Jijiwa M; Asai N; Enomoto A; Kato T; Majima A; Ping J; Murakumo Y; Takahashi M
Cancer Sci; 2007 Jun; 98(6):815-21. PubMed ID: 17388787
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
[TBL] [Abstract][Full Text] [Related]
19. An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation.
Cerchia L; D'Alessio A; Amabile G; Duconge F; Pestourie C; Tavitian B; Libri D; de Franciscis V
Mol Cancer Res; 2006 Jul; 4(7):481-8. PubMed ID: 16849523
[TBL] [Abstract][Full Text] [Related]
20. CD133: molecule of the moment.
Mizrak D; Brittan M; Alison M
J Pathol; 2008 Jan; 214(1):3-9. PubMed ID: 18067118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
